Compare OTLY & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTLY | RLMD |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.4M | 461.9M |
| IPO Year | 2021 | 2012 |
| Metric | OTLY | RLMD |
|---|---|---|
| Price | $11.89 | $3.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $14.50 | $12.40 |
| AVG Volume (30 Days) | 43.2K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $8.01 | $1.80 |
| 52 Week High | $17.18 | $8.00 |
| Indicator | OTLY | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 34.70 |
| Support Level | $10.01 | $3.34 |
| Resistance Level | $12.53 | $4.51 |
| Average True Range (ATR) | 0.49 | 0.23 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 2.30 | 21.21 |
Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.